Tempest Therapeutics Seeks Shareholder Approval for Warrants Enabling Future Capital Raises Amidst Financial Distress
TPST is trading near its 52-week low of $1.23 (4.9% above the low) on light trading volume (0.4× avg).
Summary
Tempest Therapeutics filed a definitive proxy statement seeking shareholder approval for the issuance of over 4.2 million shares underlying warrants from recent private placement and inducement offers, representing significant potential dilution.
Key Events · Financing and Capital Events · TPST
-
Shareholder Vote on Warrant Issuance
A Special Meeting of Stockholders is scheduled for June 18, 2026, to vote on two proposals to approve the issuance of shares upon the exercise of outstanding warrants.
-
Significant Potential Dilution
Shareholders are asked to approve the issuance of up to 4,278,751 shares of common stock upon the exercise of PIPE Warrants, Inducement Warrants, and Placement Agent Warrants. This represents approximately 28.9% potential dilution based on 14,806,997 outstanding shares.
-
Critical for Future Liquidity
The company states that its ability to access the capital contemplated by these agreements is important to support liquidity and fund operations, especially given its 'going concern' warning and low cash balance of $1.8 million as of Q1 2026.
-
Warrant Exercise Prices Above Current Market
The PIPE Warrants have an exercise price of $2.16 per share, and the Inducement Warrants have an exercise price of $1.73 per share. Both are above the current stock price of $1.29, meaning the warrants are currently out-of-the-money.
Analysis · TPST · Life Sciences
Tempest Therapeutics is asking shareholders to approve the issuance of shares underlying warrants from two prior financing agreements. These approvals are critical for the company to meet its obligations under the agreements and enable future capital raises, which are essential given its 'going concern' warning and low cash reserves. The potential dilution from these warrants is substantial, representing approximately 28.9% of current outstanding shares if all are exercised. While the warrant exercise prices are currently above the stock's trading price, securing shareholder approval is a necessary step for the company to access potential future liquidity.
At the time of this filing, TPST was trading at $1.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.8M. The 52-week trading range was $1.23 to $12.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.